The cell-based results corroborate the measurements from the mouse melanomas and imply that the decline in tumor growth, and the resulting improvement in survival, are mediated by the impact of exogenous ARSB on chondroitin 4-sulfation. The gene discussed is ARSB; the disease is melanoma.